Test Performance and Clinical Utility of the Cobas Eplex Blood Culture Identification Fungal Pathogen Panel
cases. However, no significant differences were observed in time to antifungal optimization, empiric therapy duration, length of stay, or mortality. Although BCID-FP offers clear diagnostic advantages, timely implementation of expert recommendations remains essential to improving outcomes.
Authors
- Ashleigh N. Riegler (ORCID: https://orcid.org/0000-0001-7939-6121)
- Sixto M. Leal (ORCID: https://orcid.org/0000-0001-6939-9572)
- Derek B. Moates
- Rachael A Lee (ORCID: https://orcid.org/0000-0002-9701-8156)
- Stefania Carmona
- J Meeder
- T P McCarty (ORCID: https://orcid.org/0009-0000-2016-8829)
Institutions
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2026-04-02
- DOI
- https://doi.org/10.1093/ofid/ofag198
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Norges Idrettshøgskole
- Roche Diagnostics